Malignant Reproductive System Neoplasm

Prostate Cancer (PCa) cell lines were either cultured alone, co-cultured with osteoblasts expressing GAS6, or cultured in the presence of media with GAS6 to examine their response to therapy with doce… (full text at CIViC)

PMID 27153245 · Lee et al., 2016 · Open in CIViC

This paper details a prospective single-arm personalized cancer therapy study with n = 16 patients. The disease type was peritoneal mucinous carcinomatosis, predominantly of appendiceal origin. Palboc… (full text at CIViC)

PMID 39413348 · Weitz et al., 2025 · Open in CIViC

Significantly shorter median progression-free survival was observed in relapsed pseudomyxoma peritonei patients with GNAS mutations (N=9; 5.3 months) as compared to wild-type (N=6; not reached; p < 0.… (full text at CIViC)

PMID 27154293 · Pietrantonio et al., 2016 · Open in CIViC

Stable GSTP1 knockdown in ovarian carcinoma A2780 cell lines showed increased sensitivity to platinum-based chemotherapy drugs carboplatin, cisplatinum, carboplatin, and paclitaxel. For each drug, 3 b… (full text at CIViC)

PMID 25010864 · Sawers et al., 2014 · Open in CIViC

G84E (rs138213197) substitution in HOXB13 is associated with an increased risk for prostate cancer. 49 out of 9012 male patients in the Mayo Clinic Biobank were carriers. 31% of patients were diagnose… (full text at CIViC)

PMID 26108461 · Beebe-Dimmer et al., 2015 · Open in CIViC

Meta-analysis of prostate cancer with sixteen case-control studies including 50,048 cases and 123,211 controls. In a random effect model the pooled OR (3.38 (95% CI: 2.45–4.66)) of the studies suppor… (full text at CIViC)

PMID 27626483 · Zhang et al., 2016 · Open in CIViC

Fresh tumor tissue 291 cervical cancer patients was fresh frozen at -70 degrees. DNA from samples was purified and analyzed via PCR for HPV 16, 18, and 6. HPV was found in 247 (85%) of tumors. HPV-16 … (full text at CIViC)

PMID 8827013 · Burger et al., 1996 · Open in CIViC

OSI-906, an IGF1R/INSR inhibitor, sensitizes cell lines to cabazitaxel, resulting in better overall survival in mouse xenografts of patient derived chemotherapy resistant castration-resistant prostate… (full text at CIViC)

PMID 25670080 · Vidal et al., 2015 · Open in CIViC

OSI-906, an IGF1R/INSR inhibitor, sensitizes cell lines to docetaxel and cabazitaxel, resulting in better overall survival in mouse xenografts of patient derived chemotherapy resistant castration-resi… (full text at CIViC)

PMID 25670080 · Vidal et al., 2015 · Open in CIViC

Phase 2 trial of capivasertib in solid cancer patients with AKT1/2/3 alterations. One patient with metastatic prostate cancer and in-frame AKT2 L78_Q79ins(HANTFVIRCL) that previously progressed on enz… (full text at CIViC)

PMID 35440569 · Shrestha Bhattarai et al., 2022 · Open in CIViC

In prostate cancer cell lines with loss of the Y-linked histone demethylase KDM5D (knockdown in LNCaP and VCaP, or deletion in LNCaP-104R2 and E006AA), ATR signaling was activated, and the selective A… (full text at CIViC)

PMID 29863497 · Komura et al., 2018 · Open in CIViC

Case Report of a 42-year old patient with low-grade endometrial stromal sarcoma. IHC was focally positive for CD117. Imatinib mesylate led to complete metabolic response (PET-CT).

PMID 18607592 · Kalender et al., 2009 · Open in CIViC

Case Report of a 41-year old patient with high-grade stromal endometrial sarcoma and a large abdominal and retroperitoneal mass progressing after chemotherapy. IHC for c-Kit was positive and treatment… (full text at CIViC)

PMID 16487996 · Salvatierra et al., 2006 · Open in CIViC

In prostate cancer (PCa) cell models (PC-3 and DU145; shRNA/siRNA knockdown of KMT2D), loss of enhancer activity markers H3K4me1/H3K27ac reduced FOXO3 protein abundance and DNA binding and suppressed … (full text at CIViC)

PMID 31232159 · Lv et al., 2019 · Open in CIViC

In this study, KRAS gain (KRAS/CEP12q ratio >1 and <2) or amplification (ratio >2) was detected in 3% (13 of 414) of the primary endometrial carcinomas investigated. Presence of KRAS gain or amplifica… (full text at CIViC)

PMID 23099803 · Birkeland et al., 2012 · Open in CIViC

In an in vitro study, a MCAS cell line expressing KRAS G12D mutation was associated with reduced sensitivity to cetuximab treatment as compared to RMUG-L and OMC-1 cells expressing wild-type KRAS. Res… (full text at CIViC)

PMID 22246397 · Sato et al., 2012 · Open in CIViC

40 patients with pseudomyxoma peritonei underwent panel sequencing after cytoreductive surgery and hypertermic intraperitoneal chemotherapy (HIPEC). KRAS mutations were found in 72% of samples and KRA… (full text at CIViC)

PMID 27502722 · Pietrantonio et al., 2016 · Open in CIViC

In an open-label, multicenter phase II study of recurrent low-grade serous ovarian cancer (ENGOT-OV60/GOG-3052/RAMP 201; NCT04625270), patients were stratified by KRAS mutation status and treated with… (full text at CIViC)

PMID 40644648 · Banerjee et al., 2025 · Open in CIViC

A 43-year-old female was diagnosed with an adenocarcinoma of the ascending colon and received 6-months of adjuvant chemotherapy. After 5 years of completion of adjuvant chemotherapy, the disease relap… (full text at CIViC)

PMID 19661358 · Palmirotta et al., 2009 · Open in CIViC

The functional variant rs61764370 in the KRAS gene 3' UTR (KRAS-variant) was found to be correlated with platinum-based chemotherapy resistance in patients with Epithelial Ovarian Cancer (EOC). 291 EO… (full text at CIViC)

PMID 22139083 · Ratner et al., 2012 · Open in CIViC

In a clinical study of 49 patients, 29 patients with Ovarian Cancer and wild-type KRAS gene were treated with Cetuximab. After 16 weeks, no clinical activity was observed. A PFS of 8 weeks (95% CI, 6.… (full text at CIViC)

PMID 33090333 · Fisher et al., 2020 · Open in CIViC

Comparison of nuclear matrix protein (NMP) patterns of paclitaxel-resistant PCa cells (DU145-TxR), with that of parental cell (DU145) using two-dimensional electrophoresis, identified cytokeratin 18 (… (full text at CIViC)

PMID 26892177 · Yin et al., 2016 · Open in CIViC

A minimum common region of deletion of 0.19Mb, encompassing exons 12–22 of LRP1B4 was observed in 4 patients exhibiting acquired treatment resistance. Transfection of mLRP1B4, a fully functional minig… (full text at CIViC)

PMID 22896685 · Cowin et al., 2012 · Open in CIViC

Case report of a 51-year old patient with recurrent low-grade serous ovarian cancer. Selumetinib treatment in a phase-II trial led to a complete and durable response > 5 years. Sequencing (MSK-IMPACT … (full text at CIViC)

PMID 26324360 · Grisham et al., 2015 · Open in CIViC

In this preclinical study, high MDM2 expressing human ovarian cancer cell lines (OVTOKO and OVMANA) exhibited resistance to t-killing cells with a dead/live ratio of 4.2:1 and 1.9:1; (P = 0.03 and P =… (full text at CIViC)

PMID 32655895 · Sahin et al., 2020 · Open in CIViC

293 cases of clinically localized prostate cancer were analyzed on needle-biopsy FFPE tissue microarray, using the MIB-1 antibody against the Ki67 marker of proliferation. IHC staining was used to gen… (full text at CIViC)

PMID 23329234 · Fisher et al., 2013 · Open in CIViC

MLH1 E13fs (c.37del), identified in a case of microsatellite-unstable endometrial cancer, was confirmed to be somatic in a 46 year old female patient (sLS-1) with suspected Lynch Syndrome (LS). The pa… (full text at CIViC)

PMID 25111426 · Geurts-Giele et al., 2014 · Open in CIViC

MLH1 G606fs*2 (c.1816_1817del), identified in a case of microsatellite-unstable endometrial cancer, was confirmed to be somatic in a 46 year old female patient (sLS-1) with suspected Lynch Syndrome (L… (full text at CIViC)

PMID 25111426 · Geurts-Giele et al., 2014 · Open in CIViC

This variant (M490T), identified in a case of microsatellite-unstable endometrial cancer was confirmed to be somatic in a 69 year-old female patient with suspected Lynch Syndrome (LS). The patient was… (full text at CIViC)

PMID 25111426 · Geurts-Giele et al., 2014 · Open in CIViC

One patient in a cohort of 50 patients with metastatic prostate cancer had a frameshift mutation in the MRE11, ATM, MLH3 and NBN genes and showed clinical response to PARP inhibitor olaparib (16 weeks… (full text at CIViC)

PMID 26510020 · Mateo et al., 2015 · Open in CIViC

One patient in a cohort of 50 patients with metastatic prostate cancer had a frameshift mutation in the MRE11 gene and showed clinical response to PARP inhibitor olaparib.

PMID 26510020 · Mateo et al., 2015 · Open in CIViC

One endometrial cell line with decreased MRE11 expression caused by a homozygous poly(T) mutation exhibited increased sensitivity to the PARP inhibitor BMN-673. Loss of MRE11 was identified in 30.7% o… (full text at CIViC)

PMID 24927325 · Koppensteiner et al., 2014 · Open in CIViC

MSH2 E483G (c.1448A > G), identified in a case of microsatellite-unstable endometrial cancer was confirmed to be somatic in a 69 year old female patient (sLS-39) with suspected Lynch Syndrome (LS). Th… (full text at CIViC)

PMID 25111426 · Geurts-Giele et al., 2014 · Open in CIViC

This variant (R383*), identified in two patients, was confirmed to be a somatic mutation in both patients' microsatellite-unstable tumors (39 year-old female with endometrial cancer & 34 year-old fema… (full text at CIViC)

PMID 25111426 · Geurts-Giele et al., 2014 · Open in CIViC

This variant (V352I), identified in a case of microsatellite-unstable endometrial cancer, was confirmed to be somatic in a 69 year-old female patient with suspected Lynch Syndrome (LS). The patient wa… (full text at CIViC)

PMID 25111426 · Geurts-Giele et al., 2014 · Open in CIViC

A phase 3 randomized trial assessed dostarlimab or placebo (combined with carboplatin-paclitaxel) in 494 patients with recurrent or primary advanced (stage III/IV) endometrial cancer (RUBY trial). End… (full text at CIViC)

PMID 36972026 · Mirza et al., 2023 · Open in CIViC

A phase 3 randomized trial assessed dostarlimab or placebo (combined with carboplatin-paclitaxel) in 494 patients with recurrent or primary advanced (stage III/IV) endometrial cancer (RUBY trial). End… (full text at CIViC)

PMID 38866180 · Powell et al., 2024 · Open in CIViC

Study of 1817 prostate adenocarcinoma cases and 2026 cancer free controls to clarify the association of (MTHFR)c.677C>T (and c.1298A>C ) of prostate cancer risk in a population of Han Chinese in Shang… (full text at CIViC)

PMID 27819322 · Wu et al., 2016 · Open in CIViC

To test for genes associated with PARPi response, a literature review of 79 publications was done, followed by CRISPR-Cas9 cell competition assays in combination with olaparib treatment in six EOC cel… (full text at CIViC)

PMID 36307400 · Coelho et al., 2022 · Open in CIViC

One 56 year old female with advanced recurrent low grade serous ovarian cancer with NRAS Q61K mutation had a partial response to trametinib, with short follow-up.

PMID 30809568 · Champer et al., 2019 · Open in CIViC

In a clinical study of 49 patients, 29 patients with Ovarian Cancer and wild-type NRAS gene were treated with Cetuximab. After 16 weeks, no clinical activity was observed. A PFS of 8 weeks (95% CI, 6.… (full text at CIViC)

PMID 33090333 · Fisher et al., 2020 · Open in CIViC

An NRG1-ERBB3 autocrine signal-transducing loop was identified in a subset of ovarian cancers and cell lines. Disruption of this loop led to decreased cell-growth in-vitro and prolonged survival in-vi… (full text at CIViC)

PMID 20227043 · Sheng et al., 2010 · Open in CIViC